GlassScriptPhysician profile
Laura A Mackley
NPI 1558622100
$6,593.85
in general payments reported to CMS, 2019-2025
31 companies · $956 in 2025
The $956 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,504 · 2022: $1,931 · 2023: $1,244 · 2024: $959 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,158.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.04 | 2021-2025 | |
| Pfizer INC. | $727.71 | 2021-2025 | |
| Novo Nordisk INC | $718.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $717.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.54 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $405.52 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
| Glaxosmithkline, LLC. | $405.12 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $289.72 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $248.74 | 2022 | |
| Amgen INC. | $213.59 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $208.91 | 2021-2024 | |
| Lilly USA, LLC | $157.80 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Biohaven Pharmaceuticals, INC. | $125.03 | 2021 | |
| Dexcom, INC. | $116.27 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $107.46 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $83.06 | 2021-2023 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $80.17 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $76.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.45 | 2021-2025 | |
| Esperion Therapeutics, INC. | $41.69 | 2021 | |
| Amarin Pharma, INC. | $40.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.05 | 2022 | |
| Eisai INC. | $35.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.03 | 2024-2025 | Xifaxan |
| Abbott Laboratories | $26.84 | 2025 | Freestyle Libre 3 |
| Nevro Corp. | $19.85 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.38 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $16.77 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.86 | 2022 | |
| Smith+Nephew, INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.